Stifel lowered the firm’s price target on Cresco Labs to C$2 from C$2.25 and keeps a Hold rating on the shares. The firm is reducing its broader core MSO market estimates by 9% in 2024 and modifying its valuation methodology for U.S. cannabis producers for “low growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>